Suchergebnisse - "Hadaschik, Boris A"

PubPharm (7)

1

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer : efficacy and predictive parameters in a large single center cohort

enthalten in: World journal of urology | 2015

von Höfner, T. | Vallet, S. | Hadaschik, B. | +5

2

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

enthalten in: World journal of urology | 2014

von Höfner, T. | Vallet, S. | Hadaschik, B. | +5

3

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

enthalten in: World journal of urology | 2014

von Höfner, T. | Vallet, S. | Hadaschik, B. | +5

4

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

enthalten in: World journal of urology | 2014

von Höfner, T. | Vallet, S. | Hadaschik, B. | +5

5

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

enthalten in: BJU international | 2008

von Sowery, R. | Hadaschik, B. | So, A. | +4

6

Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin

enthalten in: International journal of cancer | 2008

von Hadaschik, B. | Ettinger, S. | Sowery, R. | +4

7

Therapeutic options for hormone-refractory prostate cancer in 2007

enthalten in: Urologic oncology | 2007

von Hadaschik, B. | Gleave, M.

1
[1]